← Leaderboards
Adam M Brufsky
University Of Pittsburgh At Pittsburgh
$6,806,856
Attributed
$13,568,574
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,568,574 · 9
By mechanism
UG1$6,597,164 · 1
U10$4,494,569 · 1
P30$2,464,701 · 3
M01$12,140 · 4
Top collaborators
- John Munn Kirkwood14 shared
- Robert Page Edwards5 shared
- Dwight E Heron5 shared
- Mark A Socinski2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joseph P. Costantino$83,656,939
- Robert L Ferris$24,076,317
- John Munn Kirkwood$15,450,309
- Donald B Defranco$10,683,038
- Mark A Socinski$519,872
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResearch PersonnelLeadershipProgramsScienceClinical TrialsCancer CenterSiteLeadClinical ProtocolsClinical DataClinical InvestigatorData ManagementNational Clinical Trials NetworkFundingPennsylvaniaUniversity Of Pittsburgh Cancer InstituteMalignant NeoplasmsMedicalNational Cancer InstituteReportingBreast NeoplasmsOncologyDoctor Of Philosophy
Grant awards (39)
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$865,242
UG1 · FY2025 · CA · contact PI
Cancer Therapeutics Program$46,328
P30 · FY2025 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$936,542
UG1 · FY2024 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$200,000
UG1 · FY2024 · CA · contact PI
Cancer Therapeutics Program$57,679
P30 · FY2024 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076
UG1 · FY2023 · CA · contact PI
Cancer Therapeutics Program$57,679
P30 · FY2023 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$40,000
UG1 · FY2023 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076
UG1 · FY2022 · CA · contact PI
Cancer Therapeutics Program$57,679
P30 · FY2022 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076
UG1 · FY2021 · CA · contact PI
Cancer Therapeutics Program$51,178
P30 · FY2021 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076
UG1 · FY2020 · CA · contact PI
Cancer Therapeutics Program$56,772
P30 · FY2020 · CA · contact PI
NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center$911,076
UG1 · FY2019 · CA · contact PI
NCI NCTN-Network Lead Academic Site at UPCI$898,424
U10 · FY2018 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$529,651
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$8,614
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$3,972
P30 · FY2018 · CA · contact PI
NCI NCTN-Network Lead Academic Site at UPCI$898,445
U10 · FY2017 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$529,651
P30 · FY2017 · CA · contact PI
NCI NCTN-Network Lead Academic Site at UPCI$853,523
U10 · FY2016 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$532,275
P30 · FY2016 · CA · contact PI
NCI NCTN-Network Lead Academic Site at UPCI$898,445
U10 · FY2015 · CA · contact PI
Clinical Protocol and Data Management/Clinical Trials Office (Core 016)$533,223
P30 · FY2015 · CA · contact PI
NCI NCTN-Network Lead Academic Site at UPCI$945,732
U10 · FY2014 · CA · contact PI
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER$0
M01 · FY2002 · RR
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER$0
M01 · FY2002 · RR
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY$0
M01 · FY2002 · RR
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY$0
M01 · FY2002 · RR
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB$0
M01 · FY2002 · RR
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB$0
M01 · FY2002 · RR
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER$0
M01 · FY2001 · RR
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY$0
M01 · FY2001 · RR
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB$0
M01 · FY2001 · RR
SAFETY STUDY OF RECOMBINANT MONOCLONAL ANTIBODY$3,038
M01 · FY2000 · RR
RHUMABHER2/CYCLOPHOSPHAMIDE/DOXORUBICIN AND PLACEBO/CYCLOPHOSPHAMIDE/DOXORUCINB$3,034
M01 · FY2000 · RR
LIPOSOMAL ANNAMYCIN IN TAXANE RESISTANT BREAST CANCER$3,034
M01 · FY2000 · RR
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER$3,034
M01 · FY2000 · RR